TCToni L. Cordero

Toni L. Cordero

*This is an algorithmically generated author record based on publicly available information.

Toni L. Cordero has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and Validation of a Meal Detection-Based Tool for User Behavior and Meal Management Analysis

    by Andrea Benedetti, John J. Shin, Benyamin Grosman, Ohad Cohen, Robert A. Vigersky, Kamuran Turksoy, Toni L. Cordero, Anirban Roy

    Background: Management of the timing and frequency of meal announcements remains a key determinant of postprandial glycemic control in hybrid automated insulin delivery (AID) systems. Tools that translate routine device data into clinically interpretable insights on meal management behavior for individual patients and broader cohorts remain limited. These tools can potentially provide clinicians and users objective data to formulate personalized meal-related recommendations to safely improve outcomes. Methods: We developed a framework to quantify meal management behavior from routine AID data. The framework combines a meal detection model and a behavioral classification module that categorizes events as on-time, late, or missed based on temporal relationship between detected meals and carbohydrate entries. The meal detection model was trained on data from adults with type 1 diabetes using MiniMed 780G system (NCT04479826) and evaluated in a validation cohort of 157 individuals with type 1 diabetes using advanced hybrid closed-loop (AHCL) (NCT03959423) system. Results: Meal events detection accuracy reached 96.9% in the validation cohort, with precision ≥89.6%, recall ≥93.9%, and area under the curve = 0.996. Application of the tool to the validation cohort showed that a higher proportion of on-time announcements correlated with higher time in range (TIR) (ρ = 0.375, q < 0.001) and lower hyperglycemia. Each 10% increase in on-time announcements corresponded to a 2.66% increase in TIR. Increasing delay of late announcements was associated with worse postprandial glycemic outcomes. Conclusions: This framework enables insights into meal announcement patterns that may support patient counseling, clinical decision support, and large-scale analyses in AHCL systems. Clinical Trial Registration Number: NCT04479826, NCT03959423.

  • Open Access

    Real-World MiniMed ™ 780G Advanced Hybrid Closed-Loop Performance Across the Asia-Pacific Region

    by John J. Shin, Daphne Gardner, Suresh Rama Chandran, Robert A. Vigersky, Toni L. Cordero, Fang Niu, Ohad Cohen, Viswanathan Mohan, Alicia J. Jenkins, Benjamin J. Wheeler, et al.

    Aims: Diabetes mellitus (types 1 and 2) prevalence in the Asia-Pacific (APAC) region has increased significantly. While real-world evidence demonstrates MiniMed™ 780G (MM780G) system effectiveness and safety in many countries, its use in the APAC region is not well reported. The present study explored MM780G system performance and glycemic outcomes in individuals with diabetes in the APAC region. Methods: CareLink™ personal data uploaded between January 2, 2020, and March 31, 2025, by consenting APAC MM780G system users (all ages) with ≥10 days of continuous glucose monitoring (CGM) data were de-identified, aggregated, and analyzed, including a subanalysis of those using recommended optimal settings (ROS; glucose target of 100 mg/dL with an active insulin time of 2 h, for ≥95% of time). Endpoints were compared between Australia/New Zealand (AUS/NZL) and APAC without AUS/NZL (APAC w/o AUS/NZL) and assessed across quartiles of user-announced total daily carbohydrate (TDCarb). Results: Compared to AUS/NZL ( N = 17,382), APAC w/o AUS/NZL ( N = 8,360) had clinically similar and favorable CGM-derived outcomes, despite a significantly greater mean TDCarb (210.5 g vs. 147.0 g, P < 0.001). Across increasing TDCarb quartiles, for both subregions, time in range improved ( P < 0.001 for both), and time below range <70mg/dL (%TBR) was low (≤2.8%). ROS users showed further glycemic improvement with unchanged %TBR. Conclusions: The MM780G system can effectively manage real-world APAC glycemia irrespective of different TDCarb.

  • Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes

    by Halis K. Akturk, Laura M. Nally, Rayhan A. Lal, Mark L. Warren, Carla Demeterco-Berggren, Gregory P. Forlenza, John “Chip” Reed, Dorothy I. Shulman, Mark S. Kipnes, Bruce W. Bode, et al.

    Background: Given the faster onset and shorter duration of action of ultra-rapid insulin lispro-aabc (URLi, Lyumjev™ insulin), compared with insulin lispro (a rapid-acting insulin [RAI]), the present study investigated the safety and glycemic outcomes of MiniMed™ 780G advanced hybrid closed-loop (AHCL) use with URLi in youths and adults with T1D. Methods: This 19-site, single-arm, clinical trial enrolled children and adolescents (aged 7–17 years) and adults (aged 18–80 years) with T1D who underwent a run-in period (∼2 weeks) using open loop or automated basal only with an RAI (aspart or lispro), followed by a 3-month study period using URLi with AHCL (AHCL + URLi). End-of-study glycemic metrics and A1c were compared to predefined thresholds and to data from baseline/run-in. Use of recommended optimal settings (ROS, 100 mg/dL glucose target with an active insulin time [AIT] of 2 h) was also assessed. Results: In an intention-to-treat population ( N = 101 pediatric and N = 110 adult participants), percentage of time in range (%TIR) during the last ∼6 weeks of the study period was significantly greater than the predefined thresholds for both the pediatric and adult participants. A1c was unchanged in the pediatric cohort but significantly reduced in the adult cohort (from 7.4 ± 0.9% to 6.9 ± 0.6% [ P < 0.001]). Compared with run-in, study period %TIR and percentage of time in tight target range (%TITR) were significantly increased (pediatric mean %TIRΔ [17.4%] and %TITRΔ [16.0%], respectively, and adult mean %TIRΔ [10.6%] and %TITRΔ [11.6%], respectively; P < 0.001 for all). Additionally, % time above range for both groups was significantly reduced. Use of ROS allowed more participants to achieve recommended glycemic targets. There were no severe hypoglycemia or diabetic ketoacidosis events. Most caregivers agreed that mealtime versus premeal URLi delivery simplified pediatric meal management. Conclusions: Similar to previous studies investigating automated URLi delivery, URLi use in the MiniMed™ 780G system was safe, and glycemic outcomes were favorable for pediatric and adult participants.


  • MiniMed ™ 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage

    by Margaret Liu, Fang Niu, Caroline Yovanovich, Venkat Putcha, Naveen Sathiyanathan, Amanda Kinnischtzke, Diana Miller, John J. Shin, Toni L. Cordero, Robert A. Vigersky, et al.

    Socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), is associated with health disparities in diabetes management. This real-world analysis evaluated glycemic outcomes among United States users of the MiniMed ™ 780G system, stratified by ADI percentile. Data from 40,975 users revealed consistent glycemic metrics across ADI groups, with a mean time in range (TIR) of 73%, time below range (TBR) of 1.3%, and time above range (TAR) of 25%, regardless of ADI grouping. Although statistically significant associations were observed between ADI and TBR, effect sizes were minimal and not clinically meaningful. Adoption of recommended optimal settings (ROS, an active insulin time of 2 h and a glucose target of 100 mg/dL, both for >95% of the time) significantly improved outcomes, with at least 68% of users achieving consensus-recommended glycemic targets compared to ∼50% in the overall analyzed population. These findings suggest the MiniMed ™ 780G system delivers consistent glycemic outcomes across socioeconomic levels, offering a promising avenue for reducing diabetes-related health disparities.

  • Open Access

    Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States

    by Albert Chien, John J. Shin, Margaret Liu, Arcelia Arrieta, Toni L. Cordero, Andrine R. Swensen, Robert A. Vigersky

    Objective: Multiple daily injections therapy in older adults with diabetes can negatively impact glycemic control and comorbidities. This issue may be overcome with advanced diabetes technology that reduces hypoglycemia and hyperglycemia. The present study evaluated real-world glycemic outcomes of a United States (US) cohort ≥65 years using the MiniMed™ 780G (MM780G) advanced hybrid closed-loop system. Methods: CareLink™ personal data as of December 18, 2024, for U.S. MM780G system users ≥65 years, were de-identified and analyzed. Metrics, including time in range (TIR 70–180 mg/dL), time in tight range (TITR 70–140 mg/dL), time below range 70 mg/dL (TBR70), and time above range 180 mg/dL and 250 mg/dL (TAR180 and TAR250, respectively), with and without recommended optimal settings (ROS, 100 mg/dL glucose target with 2 h active insulin time) were determined. Subanalyses based on age group (≥75 years) and type 1 diabetes (T1D) or type 2 diabetes (T2D) were, also, conducted. Results: The overall cohort ( n = 8542) had a mean TIR, TITR, TBR70, TAR180, and TAR250 of 78.4%, 51.4%, 0.9%, 20.7%, and 3.6%, respectively, with a 6.8% glucose management indicator. For ROS users ( n = 2753), TIR and TITR were higher (81.9% and 55.9%, respectively, P < 0.001), and TAR180 and TAR250 were lower (17.2% and 2.5%, respectively, P < 0.001). Data trended similarly among the population aged ≥75 years, and no differences were observed between T1D and T2D. Conclusions: In a real-world setting, a U.S. cohort aged ≥65 years using the MM780G system achieved consensus-recommended glycemic targets. Use of ROS enabled more users to achieve an even higher level of glycemic control.


  • Open Access

    Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor

    by Laura M. Nally, Jennifer L. Sherr, Satish K. Garg, Brynn E. Marks, Lori M. Laffel, Catherine Pihoker, Siham D. Accacha, James R. Thrasher, M. Jennifer Abuzzahab, John H. Reed, et al.

    Introduction: The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. Materials and Methods: Youths (aged 7–17 years) and adults (aged 18–80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated. Glycemic outcomes and insulin delivery during the last 6–7 weeks of the study, when settings were optimized at investigator’s discretion, were compared with the run-in. Glycemic outcomes with the use of recommended optimal settings (ROS, 100 mg/dL glucose target with a 2-h active insulin time) were explored. Results: Time in automation was high (>93%) and mean time in range (TIR) increased from 54.4% ± 15.7% to 71.4% ± 9.9% ( P < 0.001) in youths and from 66.5% ± 12.6% to 80.2% ± 8.1% ( P < 0.001) in adults, primarily due to reduced time above range. Youths had a slight increase in time below range (TBR P < 0.001), while adults had no significant difference in TBR. For ROS users, TIR was 74.7% ± 9.3% in youths and 83.8% ± 7.4% in adults. Throughout the study ∼60% of total daily insulin dose was automated (auto basal and auto correction) in both cohorts. There were two cases of severe hypoglycemia and one episode of diabetic ketoacidosis (not related to the device). Conclusions: MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.


  • Open Access

    Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes

    by Anuj Bhargava, Richard M. Bergenstal, Mark L. Warren, James R. Thrasher, Michael A. Dempsey, Bruce W. Bode, James LaRocque, Anders L. Carlson, Ashleigh Keiter, Haoxi Ma, et al.

    Background: Early feasibility studies have demonstrated safe and effective automated insulin delivery use in individuals with suboptimally controlled type 2 diabetes (T2D). The present study investigated MiniMed™ 780G advanced hybrid closed-loop (AHCL) therapy safety and effectiveness in adults with insulin-requiring T2D. Materials and Methods: This 13-site, single-arm, open-label study included 95 adults (mean ± standard deviation [SD] age of 60.3 ± 10.8 years and T2D duration of 18.6 ± 8.6 years) using basal-bolus insulin therapy. Participants underwent a run-in period (∼21 days) of open-loop or HCL followed by a study period (∼90 days) of AHCL. The primary safety end point was mean change in glycosylated hemoglobin (HbA1c) from baseline to the end of the 3-month study period. The primary and secondary effectiveness end points were noninferiority and superiority in the percentage of time in range (%TIR 70–180 mg/dL) during the last 6 weeks of the study period (computed by the Hodges–Lehmann method). Safety metrics, including the rates of severe hypoglycemia, diabetic ketoacidosis (DKA), and hyperosmolar hyperglycemic state (HHS), were summarized. Results: HbA1c was reduced from 7.9% ± 1.0% (62.4 ± 10.4 mmol/mol) at baseline to 7.2 ± 0.7% (54.7 ± 8.0 mmol/mol) ( P < 0.001). The %TIR estimate was 80.9% (95% confidence interval: 78.4%, 83.1%), and the significance criteria for both the primary and secondary effectiveness end points were met ( P < 0.001). While total daily insulin dose was increased from run-in to the end of the study (77.4 ± 38.5 U vs. 91.8 ± 49.3 U, P < 0.0001), announced carbohydrates were unchanged, and the number of daily user-initiated boluses was reduced (3.9 ± 1.9 vs. 3.2 ± 1.8, P < 0.0001). There was no significant change in participant weight or body mass index, no severe hypoglycemia, DKA, or HHS, and no serious or unanticipated adverse device effects. Conclusions: These findings show that MiniMed 780G AHCL use provides safe insulin intensification in type 2 diabetes and significantly improves mean HbA1c and %TIR.


  • Optimizing Duration of Usage of Insulin Infusion Sets: A Response

    by Timothy Kwa, Robert A. Vigersky, Gina Zhang, Toni L. Cordero, Ohad Cohen, Sarnath Chattaraj


  • A Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection Technology

    by Benyamin Grosman, Anirban Roy, Louis Lintereur, Kamuran Turksoy, Andrea Benedetti, Toni L. Cordero, Robert A. Vigersky, Jennifer McVean, Andrew S. Rhinehart, Ohad Cohen

    The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.


  • Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States

    by James R. Thrasher, Arcelia Arrieta, Fang Niu, Katherine R. Cameron, Toni L. Cordero, John Shin, Andrew S. Rhinehart, Robert A. Vigersky

    Background: The MiniMed™ 780G system (MM780G) with Guardian™ 4 sensor includes a 100 mg/dL glucose target (GT) and automated insulin corrections up to every 5 min and was recently approved for use in the United States. In the present study, early real-world MM780G performance and the use of recommended system settings (100 mg/dL GT with an active insulin time of 2 h), by individuals with type 1 diabetes, were evaluated. Methods: CareLink™ personal data uploaded between the launch of the MM780G to August 22, 2023 were aggregated and underwent retrospective analysis (based on user consent) and if users had ≥10 days of continuous glucose monitoring (CGM) data. The 24-h day CGM metrics, including mean glucose, percentage of time spent in (%TIR), above (%TAR), and below (%TBR) target range (70–180 mg/dL), in addition to delivered insulin and closed-loop (CL) exits, were compared between an overall group ( n = 7499) and individuals who used recommended settings (each, for >95% of the time). An analysis of the same metrics for MiniMed™ 770G system (MM770G) users ( n = 3851) who upgraded to the MM780G was also conducted (paired t -test or Wilcoxon signed-rank test, P < 0.05 considered statistically significant). Results: For MM780G users, CGM use, and time in CL were >90% and all MM780G CGM metrics exceeded consensus-recommended goals. With recommended settings (22% of all users), mean %TIR and %TITR (70–140 mg/dL) were 81.4% and 56.4%, respectively. For individuals who upgraded from the MM770G, %TIR and %TITR increased from 73.2% to 78.3% and 45.8% to 52.6%, respectively, while %TAR reduced from 25.1% to 20.2% ( P < 0.001, for all three). CL exits/week averaged <1, for all MM780G users. Conclusions: Early real-world MM780G use in the United States demonstrated a high percentage of time in range with low time above and below range. These outcomes are similar to those observed for real-world MM780G use in other countries.